Gomez-Mancilla, B., Meriggioli, M. N., Genge, A., Roubenoff, R., Espié, P., Dupuy, C., . . . Jordan, B. (2023). Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study. Journal of clinical neuroscience, 119, . https://doi.org/10.1016/j.jocn.2023.11.013
Chicago-Zitierstil (17. Ausg.)Gomez-Mancilla, Baltazar, et al. "Efficacy and Safety of Iscalimab, a Novel Anti-CD40 Monoclonal Antibody, in Moderate-to-severe Myasthenia Gravis: A Phase 2 Randomized Study." Journal of Clinical Neuroscience 119 (2023). https://doi.org/10.1016/j.jocn.2023.11.013.
MLA-Zitierstil (9. Ausg.)Gomez-Mancilla, Baltazar, et al. "Efficacy and Safety of Iscalimab, a Novel Anti-CD40 Monoclonal Antibody, in Moderate-to-severe Myasthenia Gravis: A Phase 2 Randomized Study." Journal of Clinical Neuroscience, vol. 119, 2023, https://doi.org/10.1016/j.jocn.2023.11.013.